BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang HJ, Yuan GL, Liang QL, Peng XX, Cheng SA, Jiang L. Addition of bevacizumab to systemic therapy for locally advanced and metastatic nasopharyngeal carcinoma. Oncol Lett 2018;15:7799-805. [PMID: 29740494 DOI: 10.3892/ol.2018.8284] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Luo F, Lu FT, Qiu MZ, Zhou T, Ma WJ, Luo M, Zeng KM, Luo QY, Pan WT, Zhang L, Xia ZF, Zhang ZH, Cao JX, Zhao HY, Zhang L, Yang DJ. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway. Cell Death Dis 2021;12:772. [PMID: 34354046 DOI: 10.1038/s41419-021-04042-7] [Reference Citation Analysis]
2 Lee HM, Okuda KS, González FE, Patel V. Current Perspectives on Nasopharyngeal Carcinoma. Adv Exp Med Biol 2019;1164:11-34. [PMID: 31576537 DOI: 10.1007/978-3-030-22254-3_2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 10.7] [Reference Citation Analysis]
3 Zhuang M, Ding X, Song W, Chen H, Guan H, Yu Y, Zhang Z, Dong X. Correlation of IL-6 and JAK2/STAT3 signaling pathway with prognosis of nasopharyngeal carcinoma patients. Aging (Albany NY) 2021;13:16667-83. [PMID: 34165442 DOI: 10.18632/aging.203186] [Reference Citation Analysis]